SULFAMETHOXAZOLE AND TRIMETHOPRIM
LOE ApproachingNDAORALSUSPENSION
Approved
Jan 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFAMETHOXAZOLE AND TRIMETHOPRIM by Teva is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1983.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfamethoxazole and trimethoprim is a fixed-dose combination antibiotic that blocks two consecutive steps in bacterial nucleic acid synthesis by inhibiting dihydrofolic acid and tetrahydrofolic acid production. It is indicated for prosthetic joint infections and is administered orally as a suspension. The synergistic mechanism delays resistance development compared to monotherapy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect consolidation of brand team resources toward generic defense or pipeline transition activities.
Mechanism of Action
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized…
Worked on SULFAMETHOXAZOLE AND TRIMETHOPRIM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.